Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Taysha Gene Therapies ( (TSHA) ) has issued an announcement.
On October 2, 2025, Taysha Gene Therapies announced that the FDA granted Breakthrough Therapy designation to TSHA-102 for Rett syndrome, based on positive clinical evidence from their REVEAL Phase 1/2 trials. The company also finalized alignment with the FDA on the pivotal trial protocol and statistical analysis plan, aiming to expedite the Biologics License Application submission, with patient enrollment expected to begin in Q4 2025.
The most recent analyst rating on (TSHA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.
Spark’s Take on TSHA Stock
According to Spark, TipRanks’ AI Analyst, TSHA is a Neutral.
Taysha Gene Therapies’ overall stock score reflects significant financial challenges, balanced by strong clinical progress and positive technical momentum. The company’s extended cash runway and regulatory achievements are promising, but ongoing losses and valuation concerns weigh on the score.
To see Spark’s full report on TSHA stock, click here.
More about Taysha Gene Therapies
Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, targets Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies.
Average Trading Volume: 3,391,485
Technical Sentiment Signal: Buy
Current Market Cap: $867.5M
See more insights into TSHA stock on TipRanks’ Stock Analysis page.